BRIMONIDINE TARTRATE solution

Pajjiż: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

BRIMONIDINE TARTRATE (UNII: 4S9CL2DY2H) (BRIMONIDINE - UNII:E6GNX3HHTE)

Disponibbli minn:

Sandoz Inc

INN (Isem Internazzjonali):

BRIMONIDINE TARTRATE

Kompożizzjoni:

BRIMONIDINE TARTRATE 1.5 mg in 1 mL

Rotta amministrattiva:

OPHTHALMIC

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

Brimonidine tartrate ophthalmic solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Brimonidine tartrate ophthalmic solution, 0.15% is contraindicated in patients with hypersensitivity to any component of this product. Reproductive studies performed in rats and rabbits with oral doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to brimonidine tartrate ophthalmic solution, 0.15%. Dosing at this level produced an exposure in rats and rabbits that is 80 and 40 times higher than the exposure seen in humans, respectively. There are no adequate and well-controlled studies in pregnant women. In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Brimonidine tartrate ophthalmic solution, 0.15% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. It is not known whether this drug is excreted in h

Sommarju tal-prodott:

Brimonidine tartrate ophthalmic solution, 0.15% is supplied sterile in opaque white LDPE plastic bottles and natural tips with purple polypropylene caps as follows: Storage: Store at 15° to 25° C (59° to 77°F).

L-istatus ta 'awtorizzazzjoni:

New Drug Application

Karatteristiċi tal-prodott

BRIMONIDINE TARTRATE- BRIMONIDINE TARTRATE SOLUTION
SANDOZ INC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BRIMONIDINE TARTRATE
OPHTHALMIC SOLUTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION.
BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION, FOR OPHTHALMIC USE
INITIAL U.S. APPROVAL: 1996
INDICATIONS AND USAGE
Brimonidine tartrate ophthalmic solution, 0.15% is an alpha-2
adrenergic receptor agonist indicated for the
lowering of intraocular pressure in patients with open-angle glaucoma
or ocular hypertension (1).
DOSAGE AND ADMINISTRATION
•
•
DOSAGE FORMS AND STRENGTHS
Solution containing 1.5 mg/mL brimonidine tartrate (3)
CONTRAINDICATIONS
•
WARNINGS AND PRECAUTIONS
•
ADVERSE REACTIONS
Most common adverse reactions are allergic conjunctivitis,
conjunctival hyperemia, and eye pruritis (6.1).
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT SANDOZ INC. AT
1-800-525-8747 OR FDA
AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
•
•
•
•
USE IN SPECIFIC POPULATIONS
•
SEE 17 FOR PATIENT COUNSELING INFORMATION.
REVISED: 5/2021
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
Instill one drop in the affected eye(s) three-times daily (2).
If more than one topical ophthalmic product is being used, the
products should be administered at
least 5 minutes apart (2).
Hypersensitivity to any component of this product (4.1).
Potentiation of vascular insufficiency (5.1)
Concomitant use with systemic beta-blockers may potentiate systemic
beta-blockade (7.1).
Use with CNS depressants may result in an additive or potentiating
effect (7.2).
Tricyclic antidepressants may potentially blunt the hypotensive effect
of systemic clonidine (7.3).
Monoamine oxidase inhibitors may result in increased hypotension
(7.4).
Not for use in children below the age of 2 years (8.4).
4.1 Hypersensitivity
5 WARNINGS AND